De-novo Initiation of Letermovir vs Valganciclovir for Cytomegalovirus Prophylaxis in AA Kidney Trans Recip

Kidney Transplant; Complications Clinical Trial

Official title:

Historical Controlled, Single Center Open Label Pilot Comparing the Effectiveness and Tolerability of De-novo Initiation of Letermovir Versus Valganciclovir for Cytomegalovirus Prophylaxis in AA Kidney Transplant Recipients

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06001320
• Other study ID #: HM20027540
• Status: Recruiting
• Phase: Early Phase 1
• Start date: September 25, 2023
• Est. completion date: September 1, 2026

Study information

• Verified date: October 2023
• Source: Virginia Commonwealth University
• Contact: Idris Yakubu, PharmD
• Phone: 804-828-6286
• Email: idris.yakubu[@]vcuhealth.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

CMV viremia will be treated with either oral valganciclovir, intravenous ganciclovir or alternative agents, according to AST ID COP (American Society of Transplantation Infectious disease community of practice) guidelines.

Description:

Intervention: Letermovir prophylaxis. Prophylaxis is once daily dose of Letermovier starting Day 1 of post-transplant up until 6 months post-transplant.

Participants enrolled in this study will also receive prophylactic acyclovir 400mg twice daily for the duration of their Letermovir treatment.

Strategy for CMV Viremia: CMV viremia will be treated with either oral valganciclovir, intravenous ganciclovir or alternative agents, according to AST ID COP (American Society of Transplantation Infectious disease community of practice) guidelines.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: September 1, 2026
• Est. primary completion date: September 1, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Historical Control group:

Inclusion Criteria

1. Kidney transplant recipients

2. Male or female age = 18 years old

3. African American race

4. CMV high risk (D+/R-)

5. received valganciclovir for CMV prophylaxis

Historical Control group:

Exclusion

1. Re-transplantation

2. Panel of reactive antibody =80% at the time of transplant

3. Positive cytotoxic cross match at the time of transplant

Experimental Group Inclusion Criteria

1. Kidney transplant recipients

2. Male or female age = 18 years old

3. African American race

4. CMV high risk (D+/R-)

5. Ability to provide informed consent before any trial related activities

Exclusion Criteria

1. Re-transplantation

2. Panel of reactive antibody =80% at the time of transplant

3. Positive cytotoxic cross match at the time of transplant

4. Pregnancy and Breastfeeding

5. Prisoners

6. Patients with hypersensitivity to acyclovir, valacyclovir or any of its components

7. Patients with hypersensitivity to Letermovir or any of its components

8. If Patients are taking any of these medications: pimozide, ergot alkaloids (ergotamine, dihydroergotamine), or pitavastatin/simvastatin co-administered with cyclosporine, we will work with the prescribing physician to find an appropriate replacement therapy which will not interfere with any study-related interventions. Otherwise, participants will be excluded from the study.

Related Conditions & MeSH terms

• CMV
• Kidney Transplant; Complications

Intervention

Drug:
• Letermovir 480 mg once daily
We will test the study hypothesis in a single center, matched (1:1 fashion) pilot study of Letermovir 480 mg once daily versus historically matched AA kidney transplant recipients who received valganciclovir. We will enroll 50 AA patients over a 12-month period into the Letermovir group and compare outcomes to a historical group of 50 AA kidney transplant recipients who have received valganciclovir prophylaxis (1:1 fashion), for a total of 100 patients. We will attempt to match patients on Letermovir to the historical patients who received valganciclovir, based on age, kidney Donor profile index and the presence of panel of reactive antibodies.

Other:
• Historical/Control
The control study group will include high-risk African American kidney transplant recipients cared for with Valganciclovir in the 5 years prior to the enrollment start for the study group. This time frame is based upon the current volume of transplants done at VCU. On average 30 liver and/or kidney transplants are done per month. Thus, 5 years should be an adequate time frame to mine enough number of participants to answer our primary research hypothesis.

Locations

Country	Name	City	State
United States	VCU Medical Center	Richmond	Virginia

Sponsors (2)

Lead Sponsor	Collaborator
Virginia Commonwealth University	Merck Sharp & Dohme LLC

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of cytomegalovirus viremia (defined as CMV PCR > 137 units/ml) or symptomatic disease in AA kidney transplant recipients	The incidence of cytomegalovirus viremia (defined as CMV PCR > 137 units/ml) or symptomatic disease in AA kidney transplant recipients by one year post-transplantation	up to one year after transplantation
Secondary	Incidence of Leukopenia (defined as WBC < 2.5 x 103 cells/mm3 beyond the first 2 weeks of transplantation, while on pharmacologic CMV prophylaxis)	The incidence of leukopenia (defined as WBC < 2.5 x 103 cells/mm3 beyond the first 2 weeks of transplantation, while on pharmacologic CMV prophylaxis)- assessed from 2 weeks up to 26weeks post-transplant	From 2 weeks up to 26 weeks post-transplant
Secondary	Impact of Pharmacological Prophylaxis on CMV T-Cell immunity up to 1 year post-transplant	CMV T-cell immunity assay, assessed up to 1 year post-transplant. At 12, 26 and 52 weeks post-transplant	up to 1 Year post-transplant
Secondary	Incidence of acute kidney allograft rejection up to one year after transplantation	acute kidney allograft rejection up to one year after transplantation	up to 1 Year post-transplant
Secondary	Impact of Pharmacologic CMV Prophylaxis on Mycophenolate dosage up to 6 months post-transplant	Changes in mycophenolate dosage (assessed by review of patient's chart) up to 6 months post-transplant	Up to 6 months post-transplant
Secondary	Incidence of de novo donor specific antibody formation up to 1 year after transplant	de novo donor specific antibody formation up to one year after transplantation	up to 1 Year post-transplant
Secondary	Tolerability of Letermovir in AA kidney transplant recipients up to 6 months post-transplant, using a tolerability assessment questionnaire	Tolerability of Letermovir in AA kidney transplant recipient up to 6 months post-transplant (assessed through patient observation, tolerability assessment questionnaire, obtaining medical history and conduction physical examination during visits, receiving an unsolicited complaint from the participant, and an abnormal value or result from a clinical or laboratory evaluation).	up to 6 months post-transplant
Secondary	Correlation between CYP3A5*1 and its impact on tacrolimus metabolism and incidence of kidney allograft rejection up to 1 year post-transplant	correlation between CYP3A5*1 and tacrolimus metabolism and incidence of kidney allograft rejection up to one year after transplantation	up to 1 Year post-transplant